NasdaqCM - Delayed Quote • USD
Affimed N.V. (AFMD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:08 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -1.69 | -1.4 | -5.24 | -3.79 |
| Low Estimate | -1.93 | -1.62 | -6.56 | -5.37 |
| High Estimate | -1.58 | -1.01 | -3.27 | -2.63 |
| Year Ago EPS | -2.25 | -2.14 | -7.59 | -5.24 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 5 |
| Avg. Estimate | 1.15M | 970k | 5.66M | 6.58M |
| Low Estimate | 110k | -- | 1.18M | -- |
| High Estimate | 2.26M | 2.26M | 10.7M | 11.02M |
| Year Ago Sales | 5.06M | 1.47M | 8.85M | 5.66M |
| Sales Growth (year/est) | -77.30% | -34.00% | -36.10% | 16.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.09 | -2.03 | -1.97 | -1.65 |
| EPS Actual | -2.25 | -2.14 | -1.71 | -1.44 |
| Difference | -0.16 | -0.11 | 0.26 | 0.21 |
| Surprise % | -7.70% | -5.40% | 13.20% | 12.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.69 | -1.4 | -5.24 | -3.79 |
| 7 Days Ago | -1.68 | -1.39 | -5.22 | -3.77 |
| 30 Days Ago | -1.5 | -1.42 | -5.82 | -5.41 |
| 60 Days Ago | -0.14 | -0.13 | -0.62 | -0.53 |
| 90 Days Ago | -0.17 | -0.16 | -0.67 | -0.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AFMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 24.90% | -- | -- | 6.50% |
| Next Qtr. | 34.60% | -- | -- | 12.00% |
| Current Year | 31.00% | -- | -- | 5.30% |
| Next Year | 27.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/25/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/12/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Truist Securities: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Related Tickers
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
LPTX Leap Therapeutics, Inc.
3.2500
+2.52%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
PRQR ProQR Therapeutics N.V.
1.9400
-1.02%
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
MREO Mereo BioPharma Group plc
2.7400
-2.49%
ACET Adicet Bio, Inc.
1.6800
-7.18%
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%